August 6, 2026 Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery
August 6, 2026 PyroGenesis Announces Second Quarter 2026 Results: Revenue of $4.4 Million, Up 47% Year-Over-Year for Best Q2 Since 2022
